New appointments come as company strives to triple revenue by the end of 2017
TrakCel, the software developer for cell and gene therapy supply chain tracking and orchestration, has appointed a new non-executive director as it strives to triple revenue by the end of 2017.
Anthony Davies, from Dark Horse Consulting, has been recruited to join the Board of the Wales-headquartered company to strengthen its position as the leading provider of needle-to-needle cell orchestration technology to support the development and commercialisation of regenerative therapies.
After training as a biochemist, chemical engineer and molecular biologist, Davies has worked in the cell and gene therapy field for more than 20 years.
He brings with him an extensive track record in manufacturing, operational management and commercial development.
Most recently, he was Chief Technology Officer for Capricor and Vice President of product development for Geron Corporation’s cell therapy programmes.
He received an MA in Biochemistry from the University of Cambridge and a PhD in Chemical Engineering from the University of Birmingham.
At TrakCel, Davies will use his considerable experience to provide regulatory consultancy and advice on the company’s processes and governance to contribute to the firm’s growth plans.
His regulatory expertise adds to the current leadership’s strong background in clinical research, supply chain, cell therapy development and manufacture, and information technology.
Davies now joins the current board of directors which includes:
J. Matthew Mackowski: Chair and Managing Director, Telegraph Hill Partners;
Thomas A. Raffin: Senior partner, Telegraph Hill Partners;
Rob C. Hart: CFA Principal, Telegraph Hill Partners;
Ravi Nalliah: Chief Executive Officer, TrakCel;
Philip Roberts: Non-Exec Director.
Recently, TrakCel opened its second US office in New Jersey to achieve its growth targets, which include tripling its client base and revenue by the end of 2017.
The company also aims to increase its headcount to more than 100 in the UK and US by the end of 2019.